Sickle cell gene therapies offer new hope, but access remains a major challenge
FDA-approved gene therapies for sickle cell disease offer a chance to help patients, but factors including cost and access have slowed their use.
Read original article on US Top News and Analysis →Related news
- Six Flags hits record low as fatal roller coaster raises safety concerns
- Regions Financial trades higher after strong Q3 earnings, revenue beats
- Formula One price target cut to $110 at Susquehanna
- Accelerate Diversified Credit Income Fund Hedged ETF declares $0.13 dividend
-
Analysis: Everyone expects the Fed to hold rates in October. Kevin Warsh could surprise us all
- Accelerate Diversified Credit Income Fund ETF declares $0.13 dividend
- Loop outlines 45,000-tonne India plant, targets construction start in Q1 2027 and completion by end of 2028
-
SpaceX AI policy leader grilled by NYC Council on Grok safety, sexualized images